Pulmozyme Articles
Roche found guilty of UK Code violation again
9 March 2009
Pharmaxis' Bronchitol fast-tracked by FDA
18 December 2006
Pharmaxis begins UK Phase II for Bronchitol
21 February 2005
Pharmaxis begins UK Phase II for Bronchitol
21 February 2005
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Genentech's sales up 28% for 1st-qtr 2004
19 April 2004
Genentech swings to profit as sales soar
14 July 2003
Genentech
20 January 2003
Genentech 1st-qtr earnings leap
22 April 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
Genentech third-qtr revenues jump 24%
16 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
Global pulmonary drug delivery market forecasts
24 September 2001
Net income increases 28% at Genentech
12 July 2001
Aradigm and Genentech drop development of improved CF drug
6 February 2001
Genentech net income rises 30% for 2000
23 January 2001
Genentech and Aradigm initiate Phase IIa CF trial
27 January 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Roche reducing stake in Genentech
11 October 1999
New Approaches To CF Show Early Promise
20 October 1998
Rituxan Revenues Boost Genentech's 2nd Quarter
14 July 1998
Successful TOBI Launch Boosts PathoGenesis
28 May 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
First Launch For PathoGenesis' TOBI
5 January 1998
Earnings Decline At Genentech In 1st Qtr
21 April 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Pulmozyme Cleared For Advanced CF
16 December 1996
Biogen Starts Trials Of Gelsolin For Respiratory Disease
28 October 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Nerve Growth Factor For Neuropathy To Enter Ph III
21 October 1996
1996 First-Half Sales In Line At Roche
22 July 1996
Earnings Decline At Genentech In 2nd Qtr
22 July 1996
Revenues Up But Profits Down At Genentech
22 April 1996
Brussels Probes Roche Austrian "Subsidy"
4 March 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Prix Galien For Roche And Glaxo Wellcome
29 January 1996
Hoffmann-La Roche acquires rights to Genentech products
18 December 1995
No Drug Approval Lag, "At Least Not In The USA"
18 December 1995
Genentech And Roche Strengthen Relationship
6 November 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Roche Ahead Of Forecasts in 1995 First Half
4 September 1995
Genentech Takes Special Charge In 2nd Qtr
24 July 1995
NEW YORK STOCK COMMENT
24 July 1995
Genentech Growth Hormone Probe Widened
17 July 1995
Genentech Halts Pulmozyme COPD Trial
17 July 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Roche German Unit Back To Norm
20 March 1995
Genentech Starts German Distribution Project
28 November 1994
Pulmozyme For Severe CF Patients
14 November 1994
US 3rd Quarter Shows Growth Despite Pressures
24 October 1994
Genentech Presentation Pleases Analysts
17 October 1994
NEW YORK STOCK COMMENT
1 August 1994
US Biotech Cos Top Earnings At 1st Half
25 July 1994
GERMAN REFORM A BLIP SAYS ROCHE
11 July 1994
PROFITS MORE THAN DOUBLE AT GENENTECH
25 April 1994
NEW YORK STOCK COMMENT
11 April 1994
PULMOZYME AND CHRONIC BRONCHITIS
11 April 1994
GENENTECH 1st QTR MEETS FORECASTS
11 April 1994
CYSTIC FIBROSIS; WHAT COMES AFTER PULMOZYME?
7 March 1994
PULMOZYME LAUNCHED IN UK
28 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
"EXCELLENT"RESULTS FROM GENENTECH
24 January 1994
EU GIVES GO-AHEAD TO PULMOZYME
10 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
UK BIOTECH STOCKS STARTING TO MATURE
13 December 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
1994 FOR PULMOZYME BRONCHITIS TRIALS
4 October 1993
US BIOTECH PRODUCTS IN R&D (Cont'd from last issue)
4 October 1993
US PANEL BACKS CYSTIC FIBROSIS TREATMENT
16 August 1993
GENENTECH'S DNASE: PHASE II RESULTS
2 August 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
US RESEARCH INTO CYSTIC FIBROSIS
12 July 1993
US 1st QTRs IN LINE WITH EARLIER WARNINGS
26 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
GENENTECH FILES PLA FOR PULMOZYME
5 April 1993
GENENTECH LINK-UP WITH GENVEC
15 March 1993
GENENTECH PHASE III RESULTS
15 February 1993
REVENUES RISE AT GENENTECH
25 January 1993
GENENTECH DNase STUDY COMPLETED
7 December 1992
Showing 1-99 of 99 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
